Trial Results

From Associated Press (July 7, 2010)

NEW YORK -- A potential migraine headache treatment from GlaxoSmithKline and Xenoport Inc. failed to meet key treatment goals in a midstage study, the companies said Wednesday.

Shares of Xenoport Inc. plunged 27 percent, or $2.37, to $6.50 when the market opened.

The drug, labeled GSK1838262/XP13512, did not hit the target number of reduced migraine headache days experienced by patients and the companies cited an unexpectedly high response from patients taking a placebo.